I very much doubt that having a buy-back in place, particularly for a non-revenue company such as Clarity, would solve the issue regarding Short selling. If you take both Neuren and Clinuval, both of which are trading profitably, and each having instituted Share Buy-backs, and yet both have been targeted by Short sellers.
In the case of a non-revenue company such as Clarity, it would require a substantial leap of faith by anyone taking up shares far in excess of that deemed necessary to advance its business agenda, for the specific purpose of arranging a Buy-back program to thwart Short selling. And frankly it would probably result in unnecessary dilution.
CU6 Price at posting:
$1.90 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)